|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Fixed maturities available-for-sale, at fair value (amortized cost: $166.0 million and $164.6 million, respectively) | ||||||||||||||||||||
| Short-term investments, at fair value (amortized cost: $124.7 million and $187.1 million, respectively) | ||||||||||||||||||||
| Fixed maturities available-for-sale, at fair value (amortized cost: $432.9 million and $291.7 million, respectively) | ||||||||||||||||||||
| Short-term investments, at fair value (amortized cost: $67.0 million and $152.5 million, respectively) | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net of allowance of $0.3 million and $0.2 million, respectively | ||||||||||||||||||||
| Reinsurance recoverable on paid and unpaid losses and LAE | ||||||||||||||||||||
| Prepaid reinsurance premiums | ||||||||||||||||||||
| Ceding commissions receivable | ||||||||||||||||||||
| Capitalized internal use software | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Loss and loss adjustment expense reserve | ||||||||||||||||||||
| Unearned premiums | ||||||||||||||||||||
| Reinsurance premiums payable | ||||||||||||||||||||
| Provision for commission | ||||||||||||||||||||
| Fiduciary liabilities | ||||||||||||||||||||
| Contingent consideration liability | ||||||||||||||||||||
| Surplus note | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Common stock, $0.0001 par value per share; 80,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 26,384,898 and 25,699,704 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Hippo stockholders’ equity | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Common stock, shares outstanding (in shares) | ||||||||||||||||||||
Loading...
